588 related articles for article (PubMed ID: 21640043)
1. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO).
Adami S; Maugeri D; Toscano V; Topa G; Carminiti M; Brancati A; Massarotti M; Osella G; Malavolta N; Iolascon G; Cagnoni C; Camozzi V; Corradini C; Nardi A; Migliaccio S; Ulivieri FM; Resmini G; Valle D; Tauchmanovà L; Silvestri S;
Clin Exp Rheumatol; 2011; 29(3):477-84. PubMed ID: 21640043
[TBL] [Abstract][Full Text] [Related]
2. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
[TBL] [Abstract][Full Text] [Related]
3. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
[TBL] [Abstract][Full Text] [Related]
4. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).
Langdahl BL; Ljunggren Ö; Benhamou CL; Marin F; Kapetanos G; Kocjan T; Lespessailles E; Napoli N; Nikolic T; Petto H; Moll T; Lindh E
Calcif Tissue Int; 2016 Sep; 99(3):259-71. PubMed ID: 27137783
[TBL] [Abstract][Full Text] [Related]
5. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting.
Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Langdahl BL; Fahrleitner-Pammer A; Walsh JB; Gibson A; Tynan AJ; Marin F
Curr Med Res Opin; 2008 Feb; 24(2):377-84. PubMed ID: 18154690
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
7. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).
Aloumanis K; Kapetanos G; Bartzis N; Drossinos V;
BMC Musculoskelet Disord; 2015 Jun; 16():136. PubMed ID: 26044820
[TBL] [Abstract][Full Text] [Related]
9. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
[TBL] [Abstract][Full Text] [Related]
10. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
Ljunggren Ö; Barrett A; Stoykov I; Langdahl BL; Lems WF; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Karras D; Marin F
BMC Musculoskelet Disord; 2013 Aug; 14():251. PubMed ID: 23968239
[TBL] [Abstract][Full Text] [Related]
11. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
[TBL] [Abstract][Full Text] [Related]
12. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).
Langdahl BL; Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Fahrleitner-Pammer A; Walsh JB; Barker C; Kutahov A; Marin F
Calcif Tissue Int; 2009 Dec; 85(6):484-93. PubMed ID: 19823760
[TBL] [Abstract][Full Text] [Related]
13. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Lim SJ; Oh JK; Huang TW; Zeng YH; Wu MT; Yang HL; Cheung JP; Kim JW; Han JH; Huo L; Lin TJ; Zhou G; Wu WS
Clin Interv Aging; 2020; 15():111-121. PubMed ID: 32099341
[TBL] [Abstract][Full Text] [Related]
15. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
Walsh JB; Lems WF; Karras D; Langdahl BL; Ljunggren O; Fahrleitner-Pammer A; Barrett A; Rajzbaum G; Jakob F; Marin F
Calcif Tissue Int; 2012 May; 90(5):373-83. PubMed ID: 22466444
[TBL] [Abstract][Full Text] [Related]
17. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Elsalmawy AH; Ish-Shalom S; Lim SJ; Al-Ali NS; Cunha-Borges JL; Yang H; Casas N; Altan L; Moll T; Gurbuz S; Brnabic AJM; Burge RT; Marin F
Curr Med Res Opin; 2019 Jun; 35(6):1041-1049. PubMed ID: 30474449
[TBL] [Abstract][Full Text] [Related]
18. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
Oswald AJ; Berg J; Milne G; Ralston SH
Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
[No Abstract] [Full Text] [Related]
20. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
